Immune dysregulation in MDS and bone marrow failure disorders 

Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses immune dysregulation in myelodysplastic syndromes (MDS) and bone marrow failure disorders. Drawing insights from the treatment of VEXAS syndrome, an autoimmune disease with MDS-like pathology, he suggests that targeting inflammatory pathways could be a promising approach. Future research should focus on identifying the patient subset that would benefit most from this strategy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.